Allergan To Conduct Additional Tazoral Pivotal Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan receives a written response from FDA concerning the company's request for dispute resolution over the oral tazarotene NDA, which is "not approvable" at the agency. In addition to the new clinical trial, Allergan will supplement pharmacokinetic and toxicology data.
You may also be interested in...
Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA
FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products